QMUL

TCBP Provides Shareholder Update and Highlights Upcoming Milestones

Retrieved on: 
Wednesday, February 14, 2024
Therapy, Immune system, AML, FDA, QMUL, Holding, Sale, PLC, Bone marrow, Common stock, Security (finance), Kobel, IND, Research, Acute myeloid leukemia, TC, Cancer, Pharmaceutical industry

"The previous year was a time of significant operational achievement for TC BioPharm," said Bryan Kobel, Chief Executive Officer.

Key Points: 
  • "The previous year was a time of significant operational achievement for TC BioPharm," said Bryan Kobel, Chief Executive Officer.
  • We look forward/expect to continue this pattern of execution in 2024 and hitting our key milestones as laid out."
  • Entered into a collaboration agreement with Queen Mary University of London (QMUL) to expand the platform into non-oncology indications.
  • Management is focused on leveraging existing strategic relationships in order to execute partnerships and or collaborations in combination with TCB-008.

Consortium including Eco Wave Power, Toshiba, Hitachi Energy, and UK Universities Secure £1.5 Million Grant to Develop Wave-Powered Microgrid for Island in Thailand

Retrieved on: 
Thursday, February 8, 2024
Electricity, Hitachi, Economics, PEA, AIT, University, Quality of life, TEL, Organization, University of Manchester, Innovate UK, Innovation, QMUL, Research, WEC, EWP, Renewable energy

TEL AVIV, Israel, Feb. 8, 2024 /PRNewswire/ -- Eco Wave Power Global (Nasdaq: WAVE) ("Eco Wave Power" or the "Company" or "EWP"), a leading, publicly traded onshore wave energy company, is pleased to announce that  it has won a £1.5 million grant (the "Grant") as part of a consortium led by Toshiba (U.K.) and Aquatera (U.K.) to design a pilot microgrid project for a remote island in Thailand.

Key Points: 
  • The £1.5 million grant is part of Innovate UK's Energy Catalyst program Round 10, which supports U.K. and international businesses and organizations in developing market-focused technologies that provide clean, affordable and accessible energy..
  • The consortium will utilize the onshore Wave Energy Converters (WECs) developed by EWP and implement advanced technology developed by the corporate partners and the university teams.
  • Professor Guang Li, of the University of Manchester, said: "This is a second grant from Innovate UK for the development and commercialization of the Eco Wave Power's technology.
  • I also believe with our great partners we can achieve all of our objectives in this project".

Consortium including Eco Wave Power, Toshiba, Hitachi Energy, and UK Universities Secure £1.5 Million Grant to Develop Wave-Powered Microgrid for Island in Thailand

Retrieved on: 
Thursday, February 8, 2024
Electricity, Hitachi, Economics, PEA, AIT, University, Quality of life, TEL, Organization, University of Manchester, Innovate UK, Innovation, QMUL, Research, WEC, EWP, Renewable energy

TEL AVIV, Israel, Feb. 8, 2024 /PRNewswire/ -- Eco Wave Power Global (Nasdaq: WAVE) ("Eco Wave Power" or the "Company" or "EWP"), a leading, publicly traded onshore wave energy company, is pleased to announce that  it has won a £1.5 million grant (the "Grant") as part of a consortium led by Toshiba (U.K.) and Aquatera (U.K.) to design a pilot microgrid project for a remote island in Thailand.

Key Points: 
  • The £1.5 million grant is part of Innovate UK's Energy Catalyst program Round 10, which supports U.K. and international businesses and organizations in developing market-focused technologies that provide clean, affordable and accessible energy..
  • The consortium will utilize the onshore Wave Energy Converters (WECs) developed by EWP and implement advanced technology developed by the corporate partners and the university teams.
  • Professor Guang Li, of the University of Manchester, said: "This is a second grant from Innovate UK for the development and commercialization of the Eco Wave Power's technology.
  • I also believe with our great partners we can achieve all of our objectives in this project".

International Greenwich Olympiad (IGO2023): Inspiring Excellence in Innovation

Retrieved on: 
Wednesday, June 21, 2023
Park, IGO, College, Exhibition, Buckingham Palace, London Eye, Leicester Square, Oxford Street, Regent's University London, Hyde Park, Student, Regent's Park, Museum, Queen Mary University of London, QMUL, Knowledge, King's College, Interior design, Tourism, Harrods

LONDON, June 21, 2023 /PRNewswire/ -- The International Greenwich Olympiad (IGO2023), organised and sponsored by North London Grammar School (NLGS), concluded on 18th June in London, UK.

Key Points: 
  • LONDON, June 21, 2023 /PRNewswire/ -- The International Greenwich Olympiad (IGO2023), organised and sponsored by North London Grammar School (NLGS), concluded on 18th June in London, UK.
  • Partnering with the prestigious Queen Mary University London for accommodation arrangements, IGO2023 provided participants with a unique opportunity to experience the facilities designed for aspiring university students.
  • The esteemed judges were astounded by the calibre of projects on display, commenting on the high level of promise demonstrated by several entries.
  • The IGO will continue to serve as a platform for young innovators and visionaries from across the globe to showcase their remarkable projects, fostering a spirit of collaboration and inspiring excellence in innovation.

icometrix & Queen Mary University of London receive prestigious AI Award from the National Institute for Health and Care Research (NIHR) to investigate the impact of AI applied to MRI in the care of people with multiple sclerosis (MS)

Retrieved on: 
Friday, March 3, 2023
Queen Mary University of London, Care, Multiple sclerosis, Pressure, Barts Health NHS Trust, Neurology, Quality of life, InHealth Group, Nottingham University Hospitals NHS Trust, MRI, Head, Publication, Radiology, News, Software, University, DMT, Brain, Multiple Sclerosis Society, NHS, Research, MS, PPI, QMUL, Central nervous system, AI, Neuro, Patient, NIHR, Medical imaging, Pharmaceutical industry

LONDON, March 3, 2023 /PRNewswire/ -- icometrix is proud to announce that, together with Queen Mary University of London (QMUL), it has been awarded the prestigious AI Award in Health and Care. This collaborative program will investigate the impact of AI on the assessment of MRI and decision making in the context of multi-disciplinary team meetings for people with MS. It is hoped that this research will lead to better care for people with MS (pwMS).

Key Points: 
  • The programme called AssistMS, is a collaboration between icometrix, QMUL, the University of Nottingham, and Barts Health and Nottingham University Hospitals Trusts.
  • The project is further supported by the East Midlands Imaging Network (EMRAD), InHealth Group and the MS Society of Great Britain & Northern Ireland.
  • pwMS receiving disease-modifying treatments (DMT) undergo annual MRI of the central nervous system to monitor disease activity.
  • Our joint efforts will undoubtedly transform care and improve outcomes for many PwMS for the better across Europe and beyond."

icometrix & Queen Mary University of London receive prestigious AI Award from the National Institute for Health and Care Research (NIHR) to investigate the impact of AI applied to MRI in the care of people with multiple sclerosis (MS)

Retrieved on: 
Friday, March 3, 2023
Queen Mary University of London, Care, Multiple sclerosis, Pressure, Barts Health NHS Trust, Neurology, Quality of life, InHealth Group, Nottingham University Hospitals NHS Trust, MRI, Head, Publication, Radiology, News, Software, University, DMT, Brain, Multiple Sclerosis Society, NHS, Research, MS, PPI, QMUL, Central nervous system, AI, Neuro, Patient, NIHR, Medical imaging, Pharmaceutical industry

LONDON, March 3, 2023 /PRNewswire/ -- icometrix is proud to announce that, together with Queen Mary University of London (QMUL), it has been awarded the prestigious AI Award in Health and Care. This collaborative program will investigate the impact of AI on the assessment of MRI and decision making in the context of multi-disciplinary team meetings for people with MS. It is hoped that this research will lead to better care for people with MS (pwMS).

Key Points: 
  • The programme called AssistMS, is a collaboration between icometrix, QMUL, the University of Nottingham, and Barts Health and Nottingham University Hospitals Trusts.
  • The project is further supported by the East Midlands Imaging Network (EMRAD), InHealth Group and the MS Society of Great Britain & Northern Ireland.
  • pwMS receiving disease-modifying treatments (DMT) undergo annual MRI of the central nervous system to monitor disease activity.
  • Our joint efforts will undoubtedly transform care and improve outcomes for many PwMS for the better across Europe and beyond."

Alercell Is All Set to Launch a Leukemia Diagnostic Test Lena Q51(R)

Retrieved on: 
Thursday, December 29, 2022
Lung cancer, Cancer, QMUL, CMO, Biotechnology, Knowledge, DNA, LENA, Nanoparticle, Real-time, Genetic testing, Disease, Patient, Gene expression, Genome, NYSE, Infection, Genetics, Gene, Materials science, DNA methylation, Queen Mary University of London, Scheer, School, Diagnosis, Vaccine, Medical imaging, Leukemia, Engineering, Biopolymer

BOZEMAN, MT, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Alercell is all set to launch LENA Q51(R) in January 2023.

Key Points: 
  • BOZEMAN, MT, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Alercell is all set to launch LENA Q51(R) in January 2023.
  • A leukemia diagnostic test based on sequencing DNA will detect up to 51 Genes mutations in Leukemia patients.
  • The first leukemia diagnostic test, LENA Q51®, based on DNA sequencing and could identify up to 51 gene alterations in leukemia patients.
  • The first methylation-based molecular diagnostic test for lung cancer, LENA S1®, will be made available by Alercell later in the first quarter of 2023.

Eco Wave Power Reports Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Monday, February 28, 2022
United Nations, Solar Impulse, QMUL, Company, TASE, Interest, Nasdaq, Research, Climate change, The Ancient Port of Jaffa, Solar Impulse Foundation, Innovate UK, SEK, Operating cost, Founder, WEC, LSCO, Robotics, Queen Mary University of London, Engineering, OPT, Area studies, WAVE, European, Water, Electricity, USD, EDF, Floater, COP26, Jaffa Port, CET, Asian Institute of Technology, Provincial Electricity Authority, Innovation, American depositary receipt, Marketing, Technology, Port, Time, Renewable energy, Cryptocurrency

STOCKHOLM, Feb. 28, 2022 /PRNewswire/ -- Eco Wave Power Global AB (publ) (Nasdaq: WAVE, Nasdaq First North: ECOWVE) ("Eco Wave Power" or the "Company"), a leading, publicly traded onshore wave energy technology company that developed a patented, smart and cost-efficient technology for turning ocean and sea waves into green electricity, today announced financial results for the fourth quarter and full year period ended December 31, 2021, and published its year -end report for the year ended December 31, 2021.

Key Points: 
  • "Eco Wave Power enters 2022 poised for rapid and material progress," commented Inna Braverman, Founder and Chief Executive Officer of Eco Wave Power.
  • Eco Wave Power won first place in the cleantech category at the International Trade Council's 2021 Go Global Awards.
  • Inna Braverman, the Founder and Chief Executive Officer of Eco Wave Power, will discuss the results in a live video webcast at 10 a.m.
  • Eco Wave Power's mission is to assist in the fight against climate change by enabling commercial power production fromthe ocean andsea waves.

Eco Wave Power Reports Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Monday, February 28, 2022
United Nations, Solar Impulse, QMUL, Company, TASE, Interest, Nasdaq, Research, Climate change, The Ancient Port of Jaffa, Solar Impulse Foundation, Innovate UK, SEK, Operating cost, Founder, WEC, LSCO, Robotics, Queen Mary University of London, Engineering, OPT, Area studies, WAVE, European, Water, Electricity, USD, EDF, Floater, COP26, Jaffa Port, CET, Asian Institute of Technology, Provincial Electricity Authority, Innovation, American depositary receipt, Marketing, Technology, Port, Time, Renewable energy, Cryptocurrency

"Eco Wave Power enters 2022 poised for rapid and material progress," commented Inna Braverman, Founder and Chief Executive Officer of Eco Wave Power.

Key Points: 
  • "Eco Wave Power enters 2022 poised for rapid and material progress," commented Inna Braverman, Founder and Chief Executive Officer of Eco Wave Power.
  • Eco Wave Power won first place in the cleantech category at the International Trade Council's 2021 Go Global Awards.
  • Inna Braverman, the Founder and Chief Executive Officer of Eco Wave Power, will discuss the results in a live video webcast at 10 a.m.
  • Eco Wave Power's mission is to assist in the fight against climate change by enabling commercial power production fromthe ocean andsea waves.

Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop Novel Patented Molecular Signatures for Rheumatoid Arthritis Biologic Therapeutic Selection

Retrieved on: 
Sunday, January 9, 2022
Engineering, COVID-19, Silver, Social, Medical research, Humanities, Cell-bound complement activation products, Immunity, Therapy, Queen Mary University of London, Research, Patient, QMUL, St. Bartholomew's, Research Excellence Framework, London School of Hygiene & Tropical Medicine, Dentistry, Science, Lupus, U.S. Securities and Exchange Commission, Lipotriches exagens, Prognosis, Annual report, Security (finance), Education, TEF, Arthritis, Barts and The London School of Medicine and Dentistry, Private Securities Litigation Reform Act, Disease, CEO, SEC, RA, QMI, Woman, Precision medicine, Inflammation, Medicine, Student, RNA, Degenerative disease, Diagnosis, SAN, GLOBE, Rheumatoid arthritis, Center, Technology, Teaching Excellence Framework, Gene expression, Joint, Russell Group, Man, Pharmaceutical industry, Medical imaging, Rheumatology

The collaboration will focus on development and optimization of patent-pending precision medicine approaches, based on RNA expression signatures, to personalize therapeutic agent selection for rheumatoid arthritis (RA) patients.

Key Points: 
  • The collaboration will focus on development and optimization of patent-pending precision medicine approaches, based on RNA expression signatures, to personalize therapeutic agent selection for rheumatoid arthritis (RA) patients.
  • RA patients often try multiple therapies empirically before they find one that lowers their disease activity.
  • There are currently no reliable assays for predicting positive patient response prior to the selection of commonly prescribed biological therapeutic agents.
  • Queen Mary University of London is a world-leading research-intensive university with over 28,000 students representing more than 160 nationalities.